- Home
- SIGA vs GLUE Comparison
SIGA vs GLUE Comparison
Compare SIGA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | GLUE |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.6M | 1.1B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIGA | GLUE |
|---|---|---|
| Price | $6.27 | $17.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 331.4K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | 0.25 |
| Revenue | $172,249,641.00 | ★ $181,538,000.00 |
| Revenue This Year | N/A | $84.02 |
| Revenue Next Year | $132.36 | N/A |
| P/E Ratio | ★ $6.09 | $68.50 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $4.95 | $3.50 |
| 52 Week High | $9.62 | $19.17 |
Technical Indicators
Market Signals| Indicator | SIGA | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 57.21 |
| Support Level | $6.20 | $14.97 |
| Resistance Level | $6.45 | $17.81 |
| Average True Range (ATR) | 0.16 | 1.26 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 39.76 | 57.17 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.